Bausch Health posts 10% in Q2 sales, swings to profit

2023-08-03

上市批准并购财报生物类似药

Headline results for the second quarter:

Revenue: $2.2 billion, up 10%

Profit: $26 million, versus a loss of $145 million

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

CEO Thomas Appio highlighted Bausch Health's "strong performance in the second quarter as we continue to see the results from our focus on commercial excellence and investments in key businesses with growth opportunities, such as Salix." He added "we are also encouraged by various other key positive developments for our business during the quarter, including the favourable motion ruling in respect of Xifaxan."

In May, a US district court denied a motion by Norwich Pharmaceuticals that could prevent it from launching a generic version of Xifaxan for several years. The FDA has since granted tentative approval to Norwich's supplemental application, but the agency confirmed that it cannot grant final approval until October 2029. Norwich is appealing the ruling and a decision on that is expected as early as the first quarter of 2024.

Other results:

Bausch pharma: $1.1 billion, up 10%

Salix segment: $557 million, up 11%, led by Xifaxan with 9% growth

Diversified products: $228 million, down 3%

Neuro: $115 million, down 5%

Dermatology: $61 million, up 5%

Generics: $27 million, down 16%

International Rx segment: $259 million, up 11%, led by growth in Canada and the EMEA region

Bausch + Lomb: $1 billion, up 10%, boosted by the favourable impact of acquisitions and divestitures

Looking ahead:

Bausch Health, which is in the process of spinning off Bausch + Lomb, said it now expects revenues of between $8.45 billion and $8.65 billion for the year, up from an earlier target of $8.35 billion to $8.55 billion. Excluding Bausch + Lomb, revenue is forecast at $4.5 billion to $4.65 billion, whereas the company had previously forecast $4.45 billion to $4.6 billion.

Bausch Health said it "continues to believe that completing a separation of Bausch + Lomb makes strategic sense and is committed to creating two strong companies following any potential distribution."

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构